Xtalks

📬 Stay ahead with expert insights, job opportunities, and must-attend life science webinars in the December 2024 edition of the Xtalks Community Connection newsletter! 🌟 This month, we're covering exciting topics in AI, regulatory affairs, sustainability, industry trends, and new drug development technologies. Hear from industry leaders on diversity in clinical trials, explore job opportunities from entry-level to VP roles, and dive into featured articles on the tech revolution in medicine and the top pharma innovations of the year. Plus, don’t miss our poll on the trends set to shape the future of life sciences — all this and more below ⬇️ #LifeSciences #AI #Pharma #DrugDevelopment #ClinicalTrials #Sustainability #RegulatoryAffairs #TechRevolution #Innovation #Hiring

As 2024 draws to a close, we’re exploring the biggest trend in life sciences that is transforming the industry. What groundbreaking advancements will define the next decade in life sciences? Cast your vote at https://buff.ly/3BKPoAS and join the conversation on what’s driving innovation and adaptation in the industry!

Regulatory affairs professionals are the backbone of compliance and innovation in life sciences. From drug approvals to device safety, they ensure every product meets rigorous standards. Learn more about these impactful jobs at https://buff.ly/3CXC2Sn by Soumya Shashikumar.

Celltrion’s Steqeyma has joined the Stelara biosimilar lineup, addressing psoriasis and inflammatory conditions. FDA approval is supported by clinical trials showing it is highly similar to Stelara in efficacy and safety. Learn more at https://buff.ly/4ftKfLk by Soumya Shashikumar.

The FDA has approved Ensacove (ensartinib) as a first-line treatment for ALK-positive locally advanced or metastatic NSCLC. Read more at https://buff.ly/3VN9PE8 by @AyeshaR1202 about the approval and the ALK inhibitor competitors ensartinib will be going up against.

The FDA has turned down J&J’s application for a subcutaneous formulation of NSCLC drug Rybrevant (amivantamab). Read more at https://buff.ly/3DsFEvN by Ayesha Rashid about the complete response letter the agency issued to the company.

Explore how patient-centric approaches impact psychiatry clinical trials, enhancing recruitment, retention and outcomes in mental health research. Gain insights from Medpace experts Dr. James Vornov, Jill Adkins, Daniela Rae and Miaesha Campbell. Read more at https://buff.ly/41HBbzg by Vera Kovacevic. #ClinicalResearch #ClinicalTrials #MentalHealth #Psychiatry

How can we ensure diversity, equity, and inclusion (DEI) in clinical trials? Join Beatrice Doe-Printemps, MHSA and Dr. Sarah Cross, PhD from Premier Research in our latest Xtalks Spotlight as they explore DEI’s importance in clinical research. Learn how CROs are evolving trial designs to better represent diverse populations and reduce barriers to participation. Check it out here: https://buff.ly/3DbL6TH #DEI #ClinicalResearch #PatientEngagement #HealthcareEquity #PremierResearch

💡 How is AI reshaping the future of medical writing? In this Xtalks Spotlight, Maria Hopfgarten, Head of Global Medical Writing at PPD Clinical Research, Thermo Fisher Scientific, explores how the integration of AI and human intelligence (HI) is creating new efficiencies. Learn about the challenges, opportunities, and the evolving role of medical writers in an AI-assisted environment, driven by advancements in natural language processing (NLP). Watch the full interview here: https://buff.ly/49yE5bv